penicillamine has been researched along with Neutropenia in 8 studies
Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.
penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We compared the development of retinopathy of prematurity (ROP) among 49 preterm neonates:; 15 who were treated during the first 2 weeks of life with D-penicillamine and 34 who were not." | 7.74 | D-Penicillamine administration and the incidence of retinopathy of prematurity. ( Alder, SC; Baer, VL; Barraza, J; Burnett, J; Christensen, RD; Horn, JT; Lambert, DK; Richards, M; Richards, SC; Schmutz, N; Wiedmeier, SE, 2007) |
| "One hundred and one patients with rheumatoid arthritis were followed prospectively to assess the efficacy and toxicity of therapy with D-penicillamine." | 7.66 | The toxicity pattern of D-penicillamine therapy. A guide to its use in rheumatoid arthritis. ( Anastassiades, TP; Dwosh, IL; Ford, PM; Kean, WF; Kelly, HG, 1980) |
| "The mother we present is a Wilson's disease patient who had been compliant with D-penicillamine for the preceding 13 years." | 5.32 | Transient fetal myelosuppressive effect of D-penicillamine when used in pregnancy. ( Akisu, M; Aydogdu, S; Kultursay, N; Ozgenc, F; Yagci, RV; Yalaz, M, 2003) |
| "We compared the development of retinopathy of prematurity (ROP) among 49 preterm neonates:; 15 who were treated during the first 2 weeks of life with D-penicillamine and 34 who were not." | 3.74 | D-Penicillamine administration and the incidence of retinopathy of prematurity. ( Alder, SC; Baer, VL; Barraza, J; Burnett, J; Christensen, RD; Horn, JT; Lambert, DK; Richards, M; Richards, SC; Schmutz, N; Wiedmeier, SE, 2007) |
| "One hundred and one patients with rheumatoid arthritis were followed prospectively to assess the efficacy and toxicity of therapy with D-penicillamine." | 3.66 | The toxicity pattern of D-penicillamine therapy. A guide to its use in rheumatoid arthritis. ( Anastassiades, TP; Dwosh, IL; Ford, PM; Kean, WF; Kelly, HG, 1980) |
| "Many of the adverse reactions produced by penicillamine and other compounds with an active sulfhydryl group form a distinctive pattern when viewed as a class." | 2.37 | Adverse effects profile of sulfhydryl compounds in man. ( Jaffe, IA, 1986) |
| " During the treatment, clinical observations and 24-h urine copper excretion as well as adverse effects of medicines were recorded and analyzed." | 1.39 | Clinical efficacy and safety of chelation treatment with typical penicillamine in cross combination with DMPS repeatedly for Wilson's disease. ( Chen, L; Fang, F; Li, XF; Liu, Y; Xu, SQ; Zhu, HY, 2013) |
| "The mother we present is a Wilson's disease patient who had been compliant with D-penicillamine for the preceding 13 years." | 1.32 | Transient fetal myelosuppressive effect of D-penicillamine when used in pregnancy. ( Akisu, M; Aydogdu, S; Kultursay, N; Ozgenc, F; Yagci, RV; Yalaz, M, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Brooks, KV | 1 |
| Frederick, SW | 1 |
| Berryessa, NA | 1 |
| Xu, SQ | 1 |
| Li, XF | 1 |
| Zhu, HY | 1 |
| Liu, Y | 1 |
| Fang, F | 1 |
| Chen, L | 1 |
| Yalaz, M | 1 |
| Aydogdu, S | 1 |
| Ozgenc, F | 1 |
| Akisu, M | 1 |
| Kultursay, N | 1 |
| Yagci, RV | 1 |
| Christensen, RD | 1 |
| Alder, SC | 1 |
| Richards, SC | 1 |
| Lambert, DK | 1 |
| Schmutz, N | 1 |
| Wiedmeier, SE | 1 |
| Burnett, J | 1 |
| Baer, VL | 1 |
| Horn, JT | 1 |
| Richards, M | 1 |
| Barraza, J | 1 |
| Kean, WF | 1 |
| Dwosh, IL | 1 |
| Anastassiades, TP | 1 |
| Ford, PM | 1 |
| Kelly, HG | 1 |
| Perl, S | 1 |
| Jaffe, IA | 1 |
| Umeki, S | 1 |
| Konishi, Y | 1 |
| Yasuda, T | 1 |
| Morimoto, K | 1 |
| Terao, A | 1 |
1 review available for penicillamine and Neutropenia
| Article | Year |
|---|---|
Adverse effects profile of sulfhydryl compounds in man.
Topics: Anemia, Aplastic; Autoimmune Diseases; Captopril; Drug Eruptions; Glomerulonephritis; Humans; Neutro | 1986 |
7 other studies available for penicillamine and Neutropenia
| Article | Year |
|---|---|
D-penicillamine-associated neutropenia in a Doberman pinscher.
Topics: Animals; Chelating Agents; Copper; Dog Diseases; Dogs; Humans; Neutropenia; Penicillamine | 2023 |
Clinical efficacy and safety of chelation treatment with typical penicillamine in cross combination with DMPS repeatedly for Wilson's disease.
Topics: Administration, Oral; Adolescent; Chelating Agents; Chelation Therapy; Child; Copper; Drug Administr | 2013 |
Transient fetal myelosuppressive effect of D-penicillamine when used in pregnancy.
Topics: Chelating Agents; Female; Fetal Diseases; Hepatolenticular Degeneration; Humans; Infant, Newborn; Le | 2003 |
D-Penicillamine administration and the incidence of retinopathy of prematurity.
Topics: Bilirubin; Chelating Agents; Creatinine; Female; Humans; Incidence; Infant, Newborn; Male; Neutropen | 2007 |
The toxicity pattern of D-penicillamine therapy. A guide to its use in rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; Child; Digestive System; Dose-R | 1980 |
Side-effects of long-term D-penicillamine therapy in rheumatoid arthritis.
Topics: Agranulocytosis; Arthritis, Rheumatoid; Drug Eruptions; Female; Humans; Middle Aged; Neutropenia; Pe | 1977 |
D-penicillamine and neutrophilic agranulocytosis.
Topics: Agranulocytosis; Child; Female; Hepatolenticular Degeneration; Humans; Neutropenia; Penicillamine | 1985 |